Coloplast A/ S stock (DK0060448595): shares hit 5-year low on Copenhagen market weakness

Coloplast A/S shares touched a five-year low on the Nasdaq Copenhagen on 06/01/2026 as the broader Danish market declined, putting the Danish medtech group in focus for investors tracking defensive healthcare names.

Coloplast A/S shares came under pressure on the Nasdaq Copenhagen on 06/01/2026, with the stock sliding to a five-year low as part of a broader pullback in Danish equities, bringing renewed attention to the medtech group’s valuation and earnings outlook in its home market of Denmark.

According to Investing.com data as of the close of trade on 06/01/2026, Coloplast A/S (CSE: COLOb) fell 3.49% to DKK 382.00, marking the lowest closing level in roughly five years and underperforming the OMX Copenhagen 20 index, which also ended the session lower.

The stock traded at DKK 382.00 on 06/01/2026 on Nasdaq Copenhagen, according to Investing.com as of 06/01/2026, underscoring how the current market environment in Denmark has weighed on large-cap healthcare names alongside other sectors.

The move leaves Coloplast A/S trading well below the highs seen over the past several years on its primary listing in Denmark, where it is a key healthcare constituent in the local equity market and a notable component for investors following Nordic medtech stocks.

While the latest session did not bring fresh company-specific regulatory filings or earnings releases, the pronounced price action has raised questions among market participants about how macroeconomic conditions and sector rotation within the Danish market might intersect with Coloplast A/S’s fundamentals and medium-term growth profile.

In Germany, Coloplast A/S is also available via secondary trading venues such as Tradegate, providing euro-based investors with access to the Danish medtech name even as its main liquidity remains centered on Nasdaq Copenhagen.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Coloplast
• Sector/industry: Medical devices and continence & wound care
• Headquarters/country: Humlebæk, Denmark
• Core markets: Europe, North America, selected Asia-Pacific countries
• Key revenue drivers: Ostomy care, continence care, advanced wound and skin care, and interventional urology products
• Home exchange/listing venue: Nasdaq Copenhagen (COLOb)
• Trading currency: DKK

Coloplast A/S: core business model

Coloplast develops and markets medical devices for chronic care, with sales concentrated in ostomy, continence, and wound care solutions that generate recurring revenue through ongoing product usage by patients and healthcare providers.

What banks and research houses say about Coloplast A/S

No verified analyst coverage was identified at the time of publication.

Conclusion

The slide in Coloplast A/S to a five-year low on Nasdaq Copenhagen on 06/01/2026 underscores how the current risk-off mood in the Danish equity market is weighing even on defensive healthcare names.

With the stock now trading at DKK 382.00 and well below prior peaks, investors are likely to focus on how Coloplast A/S’s earnings trajectory, product portfolio in chronic care, and balance between growth and profitability might interact with broader market volatility in Denmark.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.